Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O1WR
|
|||
| Former ID |
DIB010777
|
|||
| Drug Name |
GMZ-2
|
|||
| Synonyms |
Adjuvanted PfGLURP + PfMSP3 vaccine (malaria), AMANET; GLURP-MSP3 bivalent vaccine (malaria), EMVI; Malaria vaccine (PfGLURP + PfMSP3 + aluminium hydroxide adjuvant), EMVI
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Malaria [ICD-11: 1F40-1F45; ICD-10: B50-B64, B54] | Phase 1 | [1] | |
| Company |
African Malaria Network Trust
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cell mediated immunity response (CMIR) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00424944) Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine. U.S. National Institutes of Health. | |||
| REF 2 | Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar J. 2011; 10: 359. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.